An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma

Last updated: September 11, 2025
Sponsor: Mayo Clinic
Overall Status: Completed

Phase

2

Condition

Carcinoma

Treatment

Ga-68 PSMA-11

Positron Emission Tomography

Electronic Health Record Review

Clinical Study ID

NCT06521775
24-003306
24-003306
NCI-2024-05893
  • Ages > 18
  • All Genders

Study Summary

This phase II trial tests whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful for detecting therapy response in patients with adenoid cystic carcinoma (salivary gland cancer) that has spread from where it first started (primary site) to other places in the body (metastatic). The PET scan detects and takes pictures of where the radioactive imaging agent (68Ga PSMA-11) has gone in the body and the CT scan uses x-rays to create images of the bones and internal organs within the body. Combining a PET scan with a CT scan can help make the images easier to interpret. This study may help researchers learn whether GA-68 PSMA-11 PET/CT is useful for detecting treatment response and guiding treatment decisions in patients with metastatic adenoid cystic carcinoma.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ≥ 18 years of age

  • Diagnosis of metastatic adenoid cystic carcinoma

  • Enrolled in protocol MC200708

  • Ability to tolerate a Ga68 PSMA PET/CT imaging study

  • Willingness to return for a second PSMA PET/CT scan in approximately 12-20 weeksfrom the baseline PET/CT

  • Ability to give appropriate consent or have an appropriate representative availableto do so

Exclusion

Exclusion Criteria:

  • Unable to undergo PET/CT scan

  • Not a participant in MC200708

  • < 18 years of age

  • Persons who are pregnant or nursing

  • Persons unable to consent to the study

Study Design

Total Participants: 6
Treatment Group(s): 4
Primary Treatment: Ga-68 PSMA-11
Phase: 2
Study Start date:
August 12, 2024
Estimated Completion Date:
August 12, 2025

Study Description

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of serial Ga-68 PSMA PET/CT for response assessment in metastatic adenoid cystic carcinoma.

II. Assess the correlation of PSMA PET/CT response assessment with serum extracellular vesical (EV) PSMA levels for patients undergoing treatment for metastatic adenoid cystic carcinoma.

OUTLINE:

Patients receive Ga-68 PSMA-11 intravenously (IV) and then undergo PET/CT 50-70 minutes after injection at baseline and approximately 12-20 weeks during investigational therapy.

After completion of study intervention, patients are followed up at 1 day.

Connect with a study center

  • Mayo Clinic in Rochester

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • Mayo Clinic in Rochester

    Rochester 5043473, Minnesota 5037779 55905
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.